周五的标签扩展将有助于葛兰素史克在呼吸道合胞病毒疫苗竞赛中保持领先地位。Arexvy 于 2023 年 5 月成为业内首个获得 FDA 批准的呼吸道合胞病毒疫苗，比其主要竞争对手辉瑞的 Abrysvo 提前一个月。

作为儿科医生，曾经面对呼吸道合胞病毒（RSV）感染时，总有一种无力感。但今年略有不同，因为药物预防RSV感染已取得阶段性突破。去年国内开展注射的尼塞韦单抗（乐唯初），可有效减少婴幼儿重症RSV感染的发生。01药物预防目前有三种药物预防方式：1、单克隆 ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

(RTTNews) - GSK plc (GSK, GSK.L) announced that the FDA has accepted for review an application to extend the indication of Arexvy or respiratory syncytial virus vaccine, adjuvanted to adults aged ...

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population ...

8月3日， 沃森生物 公告显示，公司与复旦大学、上海蓝鹊生物联合研发的RSV mRNA疫苗，已正式获国家药监局临床试验申请受理。这款基于自主研发mRNA技术平台的疫苗，瞄准的是预防RSV感染引起的下呼吸道相关疾病—— ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

The FDA is expected to make a decision on the expanded use of Arexvy in the first half of 2026, GSK said. European regulators are also expected to rule on a similar application by then.